SCM
AXSM icon

Semanteon Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Semanteon Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,173
Closed -$253K – 115
2025
Q1 		$253K Buy
+2,173
New +$248K 0.14% 208

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Semanteon Capital Management's AXSM Position: Q2 2025 in Review

Semanteon Capital Management sold out of Axsome Therapeutics (AXSM) in Q2 2025, closing a stake of 2,173 shares — an estimated $253K sold.

Semanteon Capital Management first reported a position in AXSM in Q1 2025 and held it in 1 quarter. The position peaked at $253K in Q1 2025. 348 funds tracked by Wall St. Rank hold AXSM as of Q2 2025.

  • Semanteon Capital Management reported no remaining Axsome Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Semanteon Capital Management sold 2,173 Axsome Therapeutics shares in Q2 2025, an estimated $253K.
  • Semanteon Capital Management first reported a position in Axsome Therapeutics in Q1 2025 and held it in 1 quarter.
  • Semanteon Capital Management's Axsome Therapeutics position peaked at $253K in Q1 2025.
  • 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2025.

Based on Semanteon Capital Management's 13F filing for Q2 2025, filed 11 Aug 2025.